Status:
COMPLETED
Retrospective Study in Sarcoma Patients
Lead Sponsor:
University Medicine Greifswald
Collaborating Sponsors:
PharmaMar
Conditions:
Sarcoma of Bone
Sarcoma of Soft Tissue
Eligibility:
All Genders
18+ years
Brief Summary
The objectives of this trial is to evaluate efficacy and safety of treatment with Trabectedin in a large cohort of German patients with soft tissue and bone sarcomas.
Eligibility Criteria
Inclusion
- Patients with histologically confirmed soft tissue or bone sarcomas treated with at least one cycle of Trabectedin in any line of therapy.
- Age ≥18years at start of therapy with Trabectedin
- Informed Consent
- Patients already deceased may be included when the treating physician is able to determine the presumptive consent
Exclusion
- No follow-up data available
Key Trial Info
Start Date :
April 18 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2021
Estimated Enrollment :
514 Patients enrolled
Trial Details
Trial ID
NCT03284320
Start Date
April 18 2017
End Date
November 1 2021
Last Update
November 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medicine Greifswald, Department of Internal Medicine C
Greifswald, Germany, 17475